These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21898040)

  • 1. Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients.
    Firouzi A; Eshraghi A; Shakerian F; Sanati HR; Salehi N; Zahedmehr A; Kiani R; Madani M; Pedarzadeh A
    Int Urol Nephrol; 2012 Aug; 44(4):1145-9. PubMed ID: 21898040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentoxifylline for the prevention of contrast-induced nephropathy in diabetic patients undergoing angioplasty: a randomized controlled trial.
    Aslanabadi N; Afsar Gharebagh R; Moharramzadeh S; Entezari-Maleki T
    Int Urol Nephrol; 2019 Apr; 51(4):699-705. PubMed ID: 30830654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention.
    Firouzi A; Maadani M; Kiani R; Shakerian F; Sanati HR; Zahedmehr A; Nabavi S; Heidarali M
    Int Urol Nephrol; 2015 Mar; 47(3):521-5. PubMed ID: 25475196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preventive effect of pentoxifylline on contrast-induced nephropathy: a randomized clinical trial.
    Yavari V; Ostovan MA; Kojuri J; Afshariani R; Hamidian Jahromi A; Roozbeh J; Pakfetrat M
    Int Urol Nephrol; 2014 Jan; 46(1):41-6. PubMed ID: 23572413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty?
    Eshraghi A; Naranji-Sani R; Pourzand H; Vojdanparast M; Morovatfar N; Ramezani J; Khamene-Bagheri R; Nezafati P
    ARYA Atheroscler; 2016 Sep; 12(5):238-242. PubMed ID: 28458699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Crisci M; Caprile M; Bigazzi MC; Palmieri R; Golia E; De Vita A; Romano IJ; Limongelli G; Russo MG; Calabrò R
    Intern Emerg Med; 2011 Dec; 6(6):503-7. PubMed ID: 21279477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial.
    Reinecke H; Fobker M; Wellmann J; Becke B; Fleiter J; Heitmeyer C; Breithardt G; Hense HW; Schaefer RM
    Clin Res Cardiol; 2007 Mar; 96(3):130-9. PubMed ID: 17180572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
    Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
    J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial.
    Vasheghani-Farahani A; Sadigh G; Kassaian SE; Khatami SM; Fotouhi A; Razavi SA; Mansournia MA; Yamini-Sharif A; Amirzadegan A; Salarifar M; Sadeghian S; Davoodi G; Borumand MA; Esfehani FA; Darabian S
    Am J Kidney Dis; 2009 Oct; 54(4):610-8. PubMed ID: 19619921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of curcumin in prevention of contrast nephropathy following coronary angiography or angioplasty in CKD patients.
    Hami M; Bigdeli A; Khameneh Bagheri R; Rajabi O; Salehi M; Zahedi Avval F
    Iran J Kidney Dis; 2019 Sep; 13(5):304-309. PubMed ID: 31705746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.